France and Romania: Comparison of recommended vaccinations
France Romania
    General recommendation
    Recommendation for specific groups only
    Catch-up (e.g. if previous doses missed)
 
Vaccination not funded by the National Health system
 
Mandatory vaccination
BirthMonthsYears
23456111216-1825611131415171819242535456574≥ 75
Coronavirus disease (COVID-19)1
COVID-197
COVID-198
tuberculosis
BCG9
BCG10
rotavirus infection
ROTA
ROTA
ROTA11
diphtheria2
D
D
D
D
d
d12
d
d13
D
D
D
D
d
tetanus2
TT
TT
TT
TT
TT
TT12
TT
TT13
TT
TT
TT
TT
TT
pertussis
acP14
acP
acP
acP
acp
acp15
acP
acP
acP
acP
acp
acp16
poliomyelitis
IPV
IPV
IPV
IPV
IPV
IPV12
IPV
IPV13
IPV
IPV
IPV
IPV
Haemophilus influenzae type b infection
Hib
Hib
Hib
Hib
Hib
Hib
hepatitis B
HepB17
HepB
HepB
HepB
HepB18
HepB19
HepB
HepB
HepB
pneumococcal disease3
PCV13
PCV13
PCV13
PCV2020
PCV
PCV
PCV
meningococcal disease4
MenB21
MenB - MenC22
MenB - MenC23
MenC24
measles5
MEAS25
MEAS
MEAS
MEAS26
MEAS27
MEAS
MEAS
mumps5
MUMPS
MUMPS
MUMPS26
MUMPS27
MUMPS
MUMPS
rubella5
RUBE
RUBE
RUBE26
RUBE28
RUBE
RUBE
human papillomavirus infection
HPV (F/M)29
HPV (F/M)30
HPV (F)31
influenza6
LAIV
IIV4
IIV3
herpes zoster
ZOS32

Footnotes:

  1. https://www.has-sante.fr/jcms/p_3197104/fr/strategie-vaccinale-contre-le-sars-cov-2
  2. Risk group vaccination of dT for pregnant women
  3. August 2023: Updated recommendations for pneumococcal vaccination published including policies on continued vaccination for those previously vaccinated with PCV13 and/or PPSV23 see https://www.has-sante.fr/jcms/p_3457419/fr/strategie-de-vaccination-contre-les-infections-a-pneumocoque-place-du-vaccin-pneumococcique-polyosidique-conjugue-20-valent-adsorbe-chez-l-adulte
  4. MenB/MenC/MenACYW vaccination: Recommendations for specific at-risk groups apply - refer to the national immunisation policy document for further information (link provided below)
  5. contacts from outbreaks of measles, mumps, rubella and flue, regardless of age
  6. For risk groups established by the World Health Organization
  7. https://www.has-sante.fr/jcms/p_3178533/fr/vaccination-dans-le-cadre-de-la-covid-19
  8. https://vaccinare-covid.gov.ro/
  9. Only recommended for children at high-risk of tuberculosis. Please refer to original document for detailled information on risk-groups.
  10. Administration during the 2-7 days after delivery
  11. 3rd dose only for pentavalent rotavirus vaccines
  12. dTacp-IPV or dTT-IPV if last dTacp-IPV received in the previous 5 years
  13. dTT-IPV every 10 years from 65 years of age
  14. or 8 weeks of age
  15. For those who did not receive a dose of pertussis containing vaccine during the past 5 years, a booster with a quadrivalent vaccine (dTacp-IPV) is recommended at the time of the Td-IPV booster at 25 years. For those aged 25 years and above that did not receive a booster dose, catch-up with a dTacp-IPV vaccine can be proposed until 39 years of age. Recommendation to have an interval of 10 years in adults between a documented pertussis and pertussis re-vaccination. Vaccination offered to pregnant women from 2nd trimester and preferably between 20 and 36 weeks of pregnancy. More information available at: calendrier_vaccinal_maj-juin23.pdf (sante.gouv.fr)
  16. Vaccination during pregnancy
  17. Babies born to a mother infected with hepatitis B will be offered a first dose at birth simultaneously with HB immunoglobulin, one month of age and 6 month of age. Four doses scheme (0-1-2-6 months) for premature <32 weeks or less than 2 kg. This intervention shall be evaluated at 9 month of age through HBs Ag and anti-HBs antibodies testing, preferably one to four month after the last vaccine dose.
  18. Three doses in a 0, 1, 6 month schedule. From 11 to 15 years, 2 doses in a 0, 6 schedule
  19. Within 24 hours after birth. In the event that the vaccine against Hepatitis B is not available, a different schedule applies for babies born of HBsAG positive mothers. More information available at: http://www.cnscbt.ro/index.php/calendarul-national-de-vaccinare
  20. From August 2023, PCV20 recommended instead of a mixed schedule PCV13+PPSV23 in adults from 18 years of age for individuals at risk. see https://www.has-sante.fr/jcms/p_3457419/fr/strategie-de-vaccination-contre-les-infections-a-pneumocoque-place-du-vaccin-pneumococcique-polyosidique-conjugue-20-valent-adsorbe-chez-l-adulte for more information
  21. Vaccination introduced in 2022.
  22. Men B introduced in 2022. Not mandatory.
  23. Men B is not mandatory.
  24. 1 dose until 24 years
  25. Update 28 June 2013:For a full description of recommendations, please refer to: http://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=362. The vaccination from 9 months of age of children entering day care was suspended. Updated recommendations - Measles vaccination for infants under 12 months of age - travelling to countries of high measles endemicity or countries with no measles elimination programmes or in case of exposure to measles cases - One dose of monovalent measles vaccines for infants aged 6 to 8 months. Thereafter 2 doses of MMR as per national recommendations. - Trivalent vaccine can be used for infants aged 9 to 11 months. Thereafter 1 dose of MMR between 12 and 15 month. of MMR are recommended as per national recommendations. In case of exposure to measles cases, administration should occur within 72 hours after exposure to the index case.
  26. 2 doses of MMR one month appart if no previous vaccination ; 1 dose if only one dose previously
  27. Two MMR doses in total among individuals born from 1980
  28. Two MMR doses in total among individuals born from 1980. For rubella, one dose of MMR among unvaccinated woman.
  29. The extension of HPV vaccination to boys aged 11 to 14 with catch-up vaccination for those aged between 15 and 19. This recommendation is applicable since January 1, 2021.
  30. Girls and boy catch-up vaccination recommended. Three-dose schedule at 0, 1-2 and 6 months
  31. Girls-only vaccination recommended. Two-dose schedule administered 6 month apart. 9-valent.
  32. for further information, please consult: http://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=389